3 results
* To assess the safety and tolerability of Ampligen administered intranasally in a dosing schedule for 13 days (7 doses) in healthy subjects.* To characterize the mucosal immune response following Ampligen administration over time.
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…
We hypothesize that a noninvasive ECGI mapping-based system, like the Amycard 01C system, can provide information valuable for both selecting patients for CRT therapy, planning the CRT procedure, guiding the actual CRT lead placement during…